Galectin Therapeutics Inc.

GALT | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.96

+$0.07 (+1.80%)

At close: Sep 21, 2026, 4:00 PM ET

$4.32

+$0.36 (+8.97%)

Pre-market: Sep 22, 2026, 8:24 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.80%

(1D)

Rating

Updated: Sep 5, 2026

17.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $260.79M

1D Range

3.85 4.02

52W Range

2.03 7.13

Valuation (TTM)

PE -9.21

PB -1.91

EV/EBITDA -28.00

Valuation (NTM)

Forward PE N/A

Forward PEG 0.40

Price Target $11

Cash Flow

FCF Yield -6.1%

SBC Adj. FCF Yield -7.0%

SBC Impact -14.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 29.0% | 9.7%

FCF 3Y | 5Y 30.1% | 8.0%

Returns

ROA -187.8%

ROE 21.5%

ROIC -1613.8%

Financial Health

Net Debt

$124.43M

Current Ratio 0.10

Interest Coverage -2.02

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disord...

Sector Healthcare

Industry Biotechnology

Employees 9

IPO Date Sep 3, 2002

Website galectintherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11

Upside

+177.78%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞